With the rapid development of lung cancer molecular detection and precisiontherapy, targeted therapy has covered the entire process of diagnosis andtreatment of nonsmall cell lung cancer patients. Overall mortality fr...With the rapid development of lung cancer molecular detection and precisiontherapy, targeted therapy has covered the entire process of diagnosis andtreatment of nonsmall cell lung cancer patients. Overall mortality from lungcancer has decreased significantly over the past 20 years, especially since theintroduction of targeted drugs in 2013. In 2022, targeted therapy for lungcancer has developed rapidly. The optimization of treatment modes and theexploration of new target drugs such as antibody‐drug conjugates will broadenthe selection range of nonsmall cell lung cancer patients with positive drivergenes. This article reviews the latest advances in targeted therapy for drivergene‐positive lung cancer in 2022.展开更多
文摘With the rapid development of lung cancer molecular detection and precisiontherapy, targeted therapy has covered the entire process of diagnosis andtreatment of nonsmall cell lung cancer patients. Overall mortality from lungcancer has decreased significantly over the past 20 years, especially since theintroduction of targeted drugs in 2013. In 2022, targeted therapy for lungcancer has developed rapidly. The optimization of treatment modes and theexploration of new target drugs such as antibody‐drug conjugates will broadenthe selection range of nonsmall cell lung cancer patients with positive drivergenes. This article reviews the latest advances in targeted therapy for drivergene‐positive lung cancer in 2022.
